Companies › Disc Medicine
3 active drug programs in 5 registered trials: 2 Phase 2, 2 Phase 1, 1 Phase 3; Hematology, Oncology, Immunology, Metabolic and endocrine; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Bitopertin (DISC-1459) Glycine transporter 1 inhibitor | SLC6A9 | Phase 3 | Erythropoietic Protoporphyria (EPP) | – |
| DISC-0974 | – | Phase 2 | Inflammatory Bowel Disease (IBD); Myelofibrosis; Anemia | Mar 2027 |
| DISC-3405 | – | Phase 2 | Polycythemia Vera (PV); Sickle Cell Disease | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06910358 | Bitopertin (DISC-1459) | Phase 3 | Erythropoietic Protoporphyria (EPP) | Metabolic and endocrine | Sep 2026 |
| NCT07368972 | DISC-0974 | Phase 2 | Inflammatory Bowel Disease (IBD) | Immunology | Mar 2027 |
| NCT05320198 | DISC-0974 | Phase 1 | Myelofibrosis; Anemia | Hematology | May 2027 |
| NCT07187973 | DISC-3405 | Phase 1 | Sickle Cell Disease | Hematology | Jun 2027 |
| NCT06985147 | DISC-3405 | Phase 2 | Polycythemia Vera (PV) | Oncology | Jul 2027 |
Cash and short-term investments of $683m on 2026-09-30; operating cash outflow about $197m a year; runway about 42 months at that burn, to Mar 2030; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 13 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
–
Karyopharm Therapeutics Agios Pharmaceuticals Theravia Omeros Syntrix Biosystems
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.